Navigation Links
Rosalind™ Launches the Next Era of Genomics
Date:9/29/2017

OnRamp BioInformatics (https://www.onramp.bio/) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers to analyze and interpret datasets, by eliminating all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, OnRamp’s Rosalind™ platform aims to simplify the practice of genomic data interpretation.

“The platform puts the researcher into the driver’s seat of data analysis,” says Tim Wesselman, CEO and Founder of OnRamp.

Rosalind™ will democratize bioinformatics by broadly expanding access to genomic and proteomic technologies for cancer research, precision medicine and sustainable agriculture.”

Over the past two decades, research technologies such as next-generation sequencing, microarray, and mass-spectrometry have become mainstream. While these technologies have driven significant medical advances, their full potential to transform personalized medicine remains constrained by the unprecedented volume and complexities of the data being generated.

OnRamp’s Rosalind™ overcomes a number of the limitations found in existing data analysis tools:

  • Complex tools require highly-trained bioinformaticians who are constantly overextended and in high demand
  • These skilled bioinformaticians spend valuable time on manual processes that could be automated so they can focus on exciting challenges and new frontiers
  • Service providers and kit companies lack scalable analysis solutions for customers using their products
  • Pharma experts continually articulate their need for robust, highly scalable data management solutions which enable them to securely and efficiently store, track, and share data.

“Top cancer research institutions have been vocal about their frustrations,” says Wesselman. “Currently, they spend thousands of dollars sequencing samples, only to receive datasets that require weeks and months of additional analysis. Rosalind™ delivers these analysis results within hours, not weeks.”

The self-guided Rosalind™ platform empowers researchers to analyze their own data. For the first time, researchers performing large-scale genomics studies across a range of fields (including drug development, precision medicine, and agri-business) can rapidly and dynamically explore and interpret their own data, accelerating their next phase of research while saving time and money.

Rosalind™ guides the researcher through the entire process, from experimental design to interpretation, for analyses including transcriptomics and epigenetics.

OnRamp CTO Jean Lozach explains how the responsive, interactive interfaces allows researchers to create their own analyses from start to finish:

“Researchers define their experimental design and upload raw data sets. Rosalind™ then performs scalable backend analyses and interpretation to generate biologically relevant results that meaningfully advance their research. This transformative experience restores the element of excitement and provides a measurable increase in productivity.”

“Advanced bioinformaticians deserve all of the credit for building state-of-the-art applications to analyze genomic, proteomic, and microarray data,” Lozach continues. “While these tools remain the lifeline of genomic analysis, more simplified user experiences are now required to empower today’s cancer biologists to focus on their research application, not which software application to use.”

Tim Wesselman concurs:

“We believe that widespread adoption of automated bioinformatic technologies will dramatically lower research costs and, ultimately, put more focus back on what to do with results, not how to get to them.”

“With Rosalind™, we’ve evolved genomic data analysis and interpretation, so our customers can get back to revolutionizing the organic world.”

About OnRamp BioInformatics
Based in the Genomics Capital of San Diego, OnRamp BioInformatics provides software and systems to streamline and simplify the analysis, data management and storage of large-scale genomic datasets so that biologists, researchers and drug developers can harness the full potential of DNA sequencing. Follow us on Twitter (@OnRampBio), or visit us at http://www.onramp.bio.

About Rosalind Franklin
Born in London, England in 1920, Rosalind Elsie Franklin studied chemistry at Cambridge, earned a research fellowship and a Ph.D. for study that aided the British war effort. Franklin went on to significantly advance our understanding of X-ray crystallography and was instrumental in the discovery of the DNA double helix. She died of ovarian cancer in 1958 at the age of 37, her contribution to the discovery of the helical structure of DNA going largely unrecognized during her lifetime.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14730163.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Institute of Food Safety and Health (IFSH) Launches Food Processing Center of Excellence in Chicago at Annual Meeting
2. Heritage Biologics launches innovative HBnow virtual care program
3. AcCELLerated Biologics Launches Distribution Partnership with CEP-Topical Gear T:25 Technology
4. BioPharma Institute Launches 5 Top U.S. Pharmaceutical & Clinical Research Industry Regulatory Compliance Courses as Parent Company Celebrates 20th Anniversary
5. The Refinery Launches 2nd Annual “Fueling the Growth” Competition
6. RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry
7. Jenway Launches Genova Bio Spectrophotometer for Life Science Applications
8. LabRoots Launches Fall STEM Scholarship for College Students
9. Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test
10. Nanomedical Diagnostics Launches New Agile Biosensor to Accelerate Label-free Drug Development
11. BellBrook Labs Launches Ultra-Sensitive Methyltransferase Assay to Accelerate Epigenetic Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):